Hope With Answers: Living With Lung Cancer

¿Cómo ayuda un navegador de pacientes a un paciente con cáncer de pulmón?

Los navegadores de pacientes pueden ayudar a entender sus opciones de tratamiento para el cáncer de pulmónUn navegador de pacientes ayuda a los pacientes a entender sus opciones de tratamiento para el cáncer de pulmón y la importancia de las últimas investigaciones y ensayos clínicos. Esto incluye asistir al paciente a través de la detección, el diagnóstico, el tratamiento y el seguimiento del cáncer de pulmón.
INVITADOS:Estelamari Rodríguez, co-directora de oncología médica torácica en el Sylvester Comprehensive Cancer Center de la Universidad de MiamiGrisel Fernández-Vega Martínez, enfermera de enlace
Grisel Fernández-Vega Martínez, enfermera de enlace
Notas del episodio | Transcripción | Versión de vídeo
 
“Primero hay que hacer un diagnóstico correcto para entender las células y entender cómo tratarlas mejor. Y creo que para cualquier paciente que tenga un diagnóstico de cáncer tan grave, que otro centro médico evalúe la patología y haga recomendaciones, abre más puertas de opciones para el paciente. ” – Dra. Estela Marks Rodriguez
 

Could CBD Oil Help Lung Cancer Patients?

In Part 2 of this Hope With Answers series on CBD, Cannabis, and Lung Cancer, we discuss the differences between CBD oil and hemp oil and what’s happening on the CBD clinical trials horizon. Once again, Jacquelyn Bainbridge, a clinical pharmacist at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus, joins us to talk about her clinical research, including work on cannabis clinical trials with hopes that CBD could help lung cancer patients.
“CBD potentially, or has a potential, to alter the immune environment and stimulate a response. So where that may be helpful is in patients with non-small cell lung cancer because it seems to be more responsive to immunotherapy. So it might be more likely to help that population.”
- Jacquelyn Brainbridge, PharmD, FCCP
Guest:
Jacquelyn Bainbridge, PharmD, FCCP: Clinical Pharmacist at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical campus
Show Notes | Watch the video | Transcript
LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.
While raising funds to support lung cancer research, LCFA will raise the public’s awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.
You can also join the conversation with LCFA on Facebook, Twitter, and Instagram. 

CBD, Cannabis, and Lung Cancer: What Does the Latest Research Say?

Could CBD and/or cannabis help lung cancer patients? A clinical pharmacist at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical campus talks about her work assisting neurology patients and her clinical research, including work on cannabis clinical trials.
In this episode, Jacci Bainbridge, clinical pharmacist, answers questions about symptomatology of CBD & cannabis, the basics about the different forms of CBD/THC, and the importance of quality clinical trials for potential improvement in lung cancer treatments involving CBD or cannabis.
Guest:Jacquelyn Bainbridge, Clinical Pharmacist at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical campus
Show Notes | Watch the Video Podcast | Transcript

Inmunoterapia para el tratamiento del cáncer de pulmón: un cambio de juego

Entendiendo los nuevos tratamientos para el cáncer de pulmón, incluyendo la inmunoterapia, que permite que su sistema inmunitario ataque las células cancerosas, es un gran avance para algunos pacientes. Sentirse seguro para pedirle a su médico que le haga pruebas para ver si la inmunoterapia o la terapia dirigida es un tratamiento apropiado es muy importante para todas las familias, pero especialmente para las familias latinas e hispanas que pueden sentirse incómodas al cuestionar a su médico. Considerando los ensayos clínicos en los que puede recibir el medicamento del mañana hoy también puede afectar significativamente los resultados del tratamiento de un paciente.
Aprenda sobre la inmunología para el cáncer de pulmón y cómo este tratamiento permite que el sistema inmunitario de un paciente ataque sus células cancerosas. La Dra. Estelamari Rodríguez y la paciente Matilde Quintana hablan sobre cómo este tratamiento innovador es un gran avance para muchos pacientes con cáncer de pulmón.
Invitadas
Dra. Estelamari Rodríguez, Co-Líder del Grupo de Enfermedades del Sitio Torácico en Sylvester Comprehensive Cancer Center.
Matilde Quintana fue diagnosticada en 2016 con cáncer de pulmón en estadio IV. Su diagnóstico actual es No Evidencia de Enfermedad (NED).
Notas del Programa | Transcripción | Versión de vídeo
Agradecida por el gran apoyo familiar y la influencia de sus raíces, Matilde quiere compartir su experiencia y sobre estos tratamientos que dan esperanza para combatir el cáncer de pulmón. Este conocimiento es especialmente necesario en las comunidades latinas e hispanas cuando se trata de importantes decisiones de atención médica, como pruebas de biomarcadores, tratamientos para el cáncer de pulmón y ensayos clínicos.

What is my biomarker? THE question to ask

What is my biomarker?
A newly diagnosed lung cancer patient should ask this question before starting treatment. Why? Because the answer to this question can change the odds and the choices for your personalized treatment plan, especially for Black or African American patients.
Black and African Americans must ask their doctors, “What is my biomarker?” to ensure they receive the latest targeted therapy treatment that is applicable. Hear from Dr. Sydney Barned and Brandi Bryant in this episode as they discuss their care and what a difference it made in knowing their biomarkers. And maybe even more importantly, they are advocating that every black or African American should ask that question, “What is my biomarker?” 
There are more options for treating lung cancer and they want to make sure every black or African American patient, like everybody, else gains access to that full range of options.
Why do Biomarkers matter in lung cancer treatment?
Minority and underserved communities must advocate for themselves to get the best treatments, especially treatment that can increase the quality of their lives. Guest Dr. Osarogiagbon dives into not only the importance of asking, “what is my biomarker?”, but why it is essential that Black and African Americans make this question a priority. Thanks to lung cancer research, he’s really excited that lots of biomarkers have been discovered to help doctors split what used to be a single disease, into a disease of many different bits and of different sizes. 
Understanding biomarkers now allows doctors to predict how the cancer is going to behave. And then determine what treatment is most likely to benefit the patient, in terms of surviving lung cancer - and the quality of life, in response to cancer treatment. 
“So, you go from 4% to 6% five-year survival, to up to 60%, if you get the right treatment for right cancer. As with ALK mutated lung cancer, so with some of the other subsets, the EGFR mutated lung cancers, the ROS1 mutated lung cancers, the BRAFF mutated lung cancers, the MET exon 14 mutated lung cancer, all... There are at least nine subsets of biomarker-driven lung cancers, and that continues to change all the time. So, that's why it's vital that we get tested, so we know which treatment would benefit us.”
- Dr. Raymond Osarogiagbon
Guests:
Dr. Sydney Barned, a hospitalist at Ann Arundel Medical Center in Annapolis, Maryland, a lung cancer patient, and a member of the LCFA Speakers Bureau
Brandi Bryant, a lung cancer patient, and a member of the LCFA Speakers Bureau
Dr. Raymond Osarogiagbon, Chief Scientist for Baptist Memorial Health Care, Director of Baptist Cancer Center’s Multidisciplinary Thoracic Oncology Program and Thoracic Oncology Research Group, and Principal Investigator of Baptist’s Mid-South Minority-Underserved Consortium initiative, NCORP, in Memphis, Tennessee
Show Notes | Transcript | Watch the video
Resources:
What Do I Need to Know About Biomarker Testing?
National Comprehensive Cancer Network (NCCN) Guidelines for Non-Small Cell Lung Cancer
What is a Liquid Biopsy for Lung Cancer?
7 Signs of Lung Cancer You Should Know

How a nurse navigator helps map lung cancer care

There is so much hope in lung cancer today. But lung cancer is also inherently very complicated. And the process of getting to a treatment plan takes a lot of expertise, different members of a medical team, and lots of tests. And one way to make this process easier on patients and more efficient for doctors who are making those treatment plans is to use an expert called a patient or nurse navigator.
Guests
Charity Holien, RN, a patient navigator with the University of Colorado Cancer CenterRoss Camidge, MD, PhD, Director of the Thoracic Oncology Clinical and Clinical Research Programs at University of Colorado Cancer Center
Video Podcast on YouTube | Transcription
Resources
A Lung Cancer Diagnosis: What’s Next
The First 7 Days podcast series
What Do I Need to Know About Biomarker Testing?
 
LCFA is a nonprofit dedicated to improving the survivorship of lung cancer patients by funding lung cancer research. Visit lcfamerica.org.

Comprender los biomarcadores del cáncer de pulmón

Un diagnóstico de cáncer de pulmón llegó de repente para Emma Pompeo. Pero afortunadamente, ella tenía dos cosas a su favor: apoyo de su familia cuando aprendió de su diagnóstico y encontró a un doctor en un centro de cáncer comprensivo que podía contestar sus preguntas en español para que ella y su familia pudieran entender toda la nueva información. Su doctor le explicó bien sobre los biomarcadores de cáncer de pulmón, organizó los exámenes requeridos, y dio buenas recomendaciones de otros doctores quienes ayudaron a formar su equipo de salud. Estos diálogos eran increíblemente importantes mientras ella aprendía el nuevo vocabulario que es parte del diagnóstico de cáncer de pulmón y del tratamiento apropiado.
INVITADOS
Dr. Christian Rolfo es un Oncólogo Torácico y experto en oncología molecular, biopsias líquidas y desarrollo de nuevos fármacos en el ámbito de cáncer de pulmón y mesotelioma en el centro de Oncología Torácica de Mount Sinai.
Emma Pompeo está viviendo con EGFR cáncer de pulmón. Ella dedica tiempo a ser una luchadora para pacientes, apoyando a otros en su experiencia con cáncer de pulmón.
Notas del Programa | Transcripción
 

What every EGFR patient needs to know

For years, researchers knew different factors were causing lung cancer tumors to grow, but they didn't know why, or how to interrupt the process. Then, a group of lung cancer researchers discovered the EGFR biomarker, which opened the door for targeted therapies that were easier to take, more effective, and led to better patient outcomes than anything used before. Take this opportunity to hear from someone who had a part in discovering the first lung cancer biomarker. Learn more about the EGFR biomarker from Dr. Carbone – important information that every EGFR patient needs to know.
Guest
Dr. David Carbone is a lung cancer clinician, researcher and specialist at The Ohio State University Comprehensive Cancer Center. He’s been working on developing treatments for lung cancer for years, and played an important role in discovering the first targeted therapy aimed at the EGFR biomarker.
Transcript | Video Podcast

EGFR Biomarker Community: Hope Living With Lung Cancer

A lung cancer diagnosis can be very overwhelming. How do you make a connection and create a sense of community with people who truly understand what you’re going through?  Hear from two people living with EGFR lung cancer who are creating connections among others with the same biomarker. Learn how sharing experiences, information, and understanding, is creating hope with answers for those in the EGFR biomarker community - while advocating for more lung cancer research.
Guests:
Jill Feldman, lung cancer patient/advocate, follow her on Twitter @jillfeldman4
Ivy Elkins, lung cancer patient/advocate, follow her on Twitter @Ivybelkins
Podcast Transcript
Meet patient advocates Jill Feldman and Ivy Elkins. They are working hard to level the playing field for people living with EGFR lung cancer by:
making sure that everyone has access to the best treatments and information
building a network of support for people living with the same type of lung cancer they have.
Resources:
What do I need to know about biomarker testing?
Targeted therapies for lung cancer treatment
EGFR Resisters, a patient-driven community dedicated to improving the outcomes for those with EGFR positive lung cancer.

Investment in grants change the future for lung cancer patients

Lung cancer is a disease that affects people: family, friends, co-workers, neighbors. It's a disease that comes with in some stark figures about survival and research funding. But the numbers don't lie, and they also show the amazing strides being made against the disease: increasing survival rates, incredible strides in treatment options, and ever-growing ranks of researchers dedicating their professional careers to improving the odds for people living with lung cancer. Join us for this episode of Hope With Answers: Living With Lung Cancer, where we talk about hope, by the numbers.
Guests:
Kim Norris, Lung Cancer Foundation of America co-founder and president
Dr. Jessica Donington, professor of surgery at the University of Chicago Pritzker School of Medicine
Dr. Triparna Sen, an assistant attending at Memorial Sloan Kettering Cancer Center
Kellie Smith, PhD, assistant professor of oncology at Johns Hopkins Medicine
 
Show Notes | Transcript
BY THE NUMBERS: 20  The quickening pace of research the last 20 years
Twenty years ago, the lung cancer treatments available were surgery, chemotherapy, and radiation. Then came the discovery of treatable lung cancer biomarkers. The discovery that each lung cancer tumor is unique opened up a whole new world of discovery. After that, immunotherapy opened up even more ways to treat different types of lung cancer. And for many people, living with lung cancer it has become more like managing a chronic disease rather than the usually fatal diagnosis it was just a handful of years ago.
“... the entire landscape has changed for people diagnosed with lung cancer. I even wonder if my husband, who died 20 years ago, would still be alive if he had been able to take advantage of all the research that’s been happening in just the past five or ten years. We now know people living 8, 13, 15, and 19 years after diagnosis. And then we realized that these numbers are really powerful-- they’re not just black and white numbers, they’re people.“ - Kim Norris
BY THE NUMBERS: Double Duty
LCFA Young Investigator Research Grants do double duty in the field of lung cancer research. Funding from foundations like the Lung Cancer Foundation of America is essential in building a pool of investigators. It takes a long time and a lot of money to go from a great idea and a bright star with a great mind to an NIH-funded investigator. But as Dr. Triparna Sen points out, these grants also help to train young investigators.
“Like with this funding, we get postdocs and trainees and technicians into the lab. So we are essentially training the next generation of cancer investigators who will go on to become in independent investigators themselves. So you're not only just providing resource to advanced research, but you're also providing resource to train the next generation of cancer investigators. And I think that has a much more long term impact the next clinical trial. So I think overall, uh, the funding that I got from LCFA has been absolutely critical in developing me as a researcher. So thank you so much.”
BY THE NUMBERS: 17
LCFA has invested in 17 grants so far, and 10 of them have gone to women.
Women in science face many challenges. When Dr. Donington got into lung cancer 15 years ago, it was a very male-dominated field in terms of the doctors who treated it and the researchers who performed the research. And I always believe that a group of physicians and researchers that matches their patients provides the best care.
The Power Of The Patient Advocate Voice
Women advocates are making a difference in lung cancer research as well. As Dr. Donington discusses, “Lung cancer for a long time has had a stigma issue as being seen as a male disease, with people who have smoked for 100 years. And it's just not, it's not that disease. And I think that our advocates which are very heavily female like a lot of cancer advocates are, have really done so much to change the face of lung cancer…. I think they do more to change lung cancer than even us as investigators.” Dr. Sen thinks that what the patient advocates do is they help bring system-wide issues to light that are required for clinical trial design for what is important for the actual patients who is the ultimate goal role for our researchers. And her goal is to work with patient advocates to make her scientific studies more relevant to the field, more timely, because she now understand by speaking to them the urgency of the situation, and so make it more timely.
“And I think patient advocates play a very important role to help researchers learn like myself move discoveries towards clinical use, but do that in a more sort of not only timely fashion, but also help us design studies that are more relevant to clinical use.” - Dr. Triparna Sen
In addition, patient advocates play an important role in bringing these disparities to light. Then these issues can be addressed by researchers and by clinicians and move them to incorporating equity in clinical trial.
“I think so they play a very important role at multiple levels and LCFA has done an incredible job in connecting researchers to patient advocates.” - Dr. Triparna Sen
The Pace of Research: Bench to Bedside
“And I didn't think it was possible in my lifetime, but I suddenly think that, oh my gosh, we can double survival. We can get survival up to 25 and 30%. I feel like in a very short time, uh, with screening and the advancements in our current medications, it's just so possible. It's exciting.” - Dr. Jessica Donington
The time it takes for research to go from bench to bedside is getting faster all time. That’s the timeline: how long it takes for a discovery in the lab to make it to a patient who needs it. So, for example, when you're in a laboratory you hear about using mice and discoveries, but that's just in theory, then you have to bring it to the human and that takes time.
“Bench to bedside has never been as fast as it is now in lung cancer. It is incredible. Things we never considered as little as five years ago are just commonplace now. It was very funny I was working with one of my colleagues and she said, "Oh, yeah, I don't treat one person the same way I did five years ago as a medical oncologist." And then I sat down and go, "Oh, you know what? I don't either." Like none of us do. So there's this whole synergy about the science too, as it advances in one area, it becomes easier to integrate it into others and it's really exciting.” - Dr. Jessica Donington
Research breakthroughs discovered five, six years ago are already in clinical trials.  So this bench to bedside medicine is a phenomenal thing to be a part of within the context of lung cancer.
“As a PhD scientist, we very rarely see the fruits of our labor actually pan out in the clinic. I mean, it's very rare. But with lung cancer research, because it's moving at such a rapid pace, we are able to see these discoveries making their way into the clinic in an accelerated timeframe.” - Dr. Kellie Smith
Research = Hope
The goal of LCFA’s Young Investigator grant program is to attract the best and brightest minds into lung cancer research early in their careers. This LCFA grant is big enough that they can set up their labs and gather that first big collection of data.Then, they can use this data to apply for even larger grants that may one day lead to clinical trials and hopefully new treatments.
BY THE NUMBERS: Investment in Grants $200,000 >> $4 Million
Kellie Smith is a shining example of LCFA’s mission. Using her LCFA grants, she was generated preliminary data, made these really impactful discoveries, and then to applied for additional funding.
“And, just based on my own personal experience, the LCFA Young Investigator award was the very first grant that I was ever awarded. I've been able to leverage that now into several million dollars worth of funding.”